FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089195565> ?p ?o ?g. }

• W2089195565 endingPage "1757" @default.
• W2089195565 startingPage "1750" @default.
• W2089195565 abstract "BACKGROUND Continuous oral treatment with topotecan may be more effective than the typical 1-day and 5-day treatment schedules. In previous studies of continuous treatment with topotecan, increased intestinal side effects were reported in adult patients; however, the experience in pediatric patients and patients with high-grade glioma is quite limited. METHODS Thirty-two pediatric patients with recurrent high-grade glioma (16 females and 16 males; median age, 9.5 years) were enrolled in the current Phase I/II study. Tumor locations included the cerebral cortex (n = 5), pons (n = 18), and other sites (n = 9). An injectable formulation of topotecan was administered orally, in ice-cold orange juice, once daily. The starting dose of 0.4 mg/m2 per day was escalated on a patient-by-patient basis. At each patient's maximum dose, blood samples were obtained for the determination of plasma hydroxytopotecan and topotecan lactone concentrations and for the calculation of pharmacokinetic quantities. RESULTS The toxicity criteria for a maximum tolerated topotecan dose were met in only 19 patients. The primary toxicity type was hematologic. The median maximum tolerated dose was 0.9 mg/m2 per day (n = 19). The calculated maximum total plasma topotecan concentration was 3.8 ng/mL (n = 7), with an area under the concentration-time curve of 38.4 ng · hours/mL and a half-life of 4.1 hours, which would result in the complete disappearance of topotecan from the plasma after 12 hours. Objective responses were observed in 2 of 13 evaluable patients and lasted for 2.5 and 9 months, respectively (continuous clinical remission, 1 of 14 patients; partial response, 2 of 14 patients; stable disease, 7 of 14 patients; progressive disease, 4 of 14 patients). CONCLUSIONS Oral topotecan (median dose, 0.9 mg/m2 per day) administered once daily was well tolerated and somewhat effective in children with recurrent high-grade glioma. A schedule in which the daily dose is split so that dosing is performed twice daily may be superior to the current schedule. Cancer 2004. © 2004 American Cancer Society." @default.
• W2089195565 created "2016-06-24" @default.
• W2089195565 creator A5017088990 @default.
• W2089195565 creator A5021118632 @default.
• W2089195565 creator A5027129597 @default.
• W2089195565 creator A5040862229 @default.
• W2089195565 creator A5043604991 @default.
• W2089195565 creator A5044289994 @default.
• W2089195565 creator A5046123788 @default.
• W2089195565 creator A5050173594 @default.
• W2089195565 creator A5062013948 @default.
• W2089195565 creator A5072059758 @default.
• W2089195565 creator A5085106672 @default.
• W2089195565 date "2004-03-11" @default.
• W2089195565 modified "2023-10-16" @default.
• W2089195565 title "Oral topotecan in children with recurrent or progressive high-grade glioma" @default.
• W2089195565 cites W1767413501 @default.
• W2089195565 cites W1859729923 @default.
• W2089195565 cites W1882320586 @default.
• W2089195565 cites W1883759477 @default.
• W2089195565 cites W1935226228 @default.
• W2089195565 cites W1965490017 @default.
• W2089195565 cites W1974908229 @default.
• W2089195565 cites W1983612486 @default.
• W2089195565 cites W1993693471 @default.
• W2089195565 cites W1997712655 @default.
• W2089195565 cites W2011909208 @default.
• W2089195565 cites W2012797500 @default.
• W2089195565 cites W2022929237 @default.
• W2089195565 cites W2037685031 @default.
• W2089195565 cites W2051536172 @default.
• W2089195565 cites W2064761842 @default.
• W2089195565 cites W2070540557 @default.
• W2089195565 cites W2077422649 @default.
• W2089195565 cites W2079245784 @default.
• W2089195565 cites W2092998745 @default.
• W2089195565 cites W2094898536 @default.
• W2089195565 cites W2157392358 @default.
• W2089195565 cites W2170845869 @default.
• W2089195565 cites W2474076749 @default.
• W2089195565 cites W288844979 @default.
• W2089195565 cites W4243866615 @default.
• W2089195565 doi "https://doi.org/10.1002/cncr.20168" @default.
• W2089195565 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15073866" @default.
• W2089195565 hasPublicationYear "2004" @default.
• W2089195565 type Work @default.
• W2089195565 sameAs 2089195565 @default.
• W2089195565 citedByCount "21" @default.
• W2089195565 countsByYear W20891955652012 @default.
• W2089195565 countsByYear W20891955652016 @default.
• W2089195565 countsByYear W20891955652017 @default.
• W2089195565 countsByYear W20891955652019 @default.
• W2089195565 countsByYear W20891955652021 @default.
• W2089195565 countsByYear W20891955652023 @default.
• W2089195565 crossrefType "journal-article" @default.
• W2089195565 hasAuthorship W2089195565A5017088990 @default.
• W2089195565 hasAuthorship W2089195565A5021118632 @default.
• W2089195565 hasAuthorship W2089195565A5027129597 @default.
• W2089195565 hasAuthorship W2089195565A5040862229 @default.
• W2089195565 hasAuthorship W2089195565A5043604991 @default.
• W2089195565 hasAuthorship W2089195565A5044289994 @default.
• W2089195565 hasAuthorship W2089195565A5046123788 @default.
• W2089195565 hasAuthorship W2089195565A5050173594 @default.
• W2089195565 hasAuthorship W2089195565A5062013948 @default.
• W2089195565 hasAuthorship W2089195565A5072059758 @default.
• W2089195565 hasAuthorship W2089195565A5085106672 @default.
• W2089195565 hasBestOaLocation W20891955651 @default.
• W2089195565 hasConcept C112705442 @default.
• W2089195565 hasConcept C126322002 @default.
• W2089195565 hasConcept C141071460 @default.
• W2089195565 hasConcept C2776694085 @default.
• W2089195565 hasConcept C2778227246 @default.
• W2089195565 hasConcept C2781209748 @default.
• W2089195565 hasConcept C29730261 @default.
• W2089195565 hasConcept C42219234 @default.
• W2089195565 hasConcept C502942594 @default.
• W2089195565 hasConcept C71924100 @default.
• W2089195565 hasConcept C90924648 @default.
• W2089195565 hasConceptScore W2089195565C112705442 @default.
• W2089195565 hasConceptScore W2089195565C126322002 @default.
• W2089195565 hasConceptScore W2089195565C141071460 @default.
• W2089195565 hasConceptScore W2089195565C2776694085 @default.
• W2089195565 hasConceptScore W2089195565C2778227246 @default.
• W2089195565 hasConceptScore W2089195565C2781209748 @default.
• W2089195565 hasConceptScore W2089195565C29730261 @default.
• W2089195565 hasConceptScore W2089195565C42219234 @default.
• W2089195565 hasConceptScore W2089195565C502942594 @default.
• W2089195565 hasConceptScore W2089195565C71924100 @default.
• W2089195565 hasConceptScore W2089195565C90924648 @default.
• W2089195565 hasIssue "8" @default.
• W2089195565 hasLocation W20891955651 @default.
• W2089195565 hasLocation W20891955652 @default.
• W2089195565 hasOpenAccess W2089195565 @default.
• W2089195565 hasPrimaryLocation W20891955651 @default.
• W2089195565 hasRelatedWork W1672428922 @default.
• W2089195565 hasRelatedWork W1972477507 @default.
• W2089195565 hasRelatedWork W2001615357 @default.
• W2089195565 hasRelatedWork W2003938723 @default.

• next